Meeting
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
Authors
Srikala S. Sridhar
Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
Srikala S. Sridhar , Thomas Powles , Shilpa Gupta , Miguel Ángel Climent , Jeanny B. Aragon-Ching , Cora N. Sternberg , Paul Cislo , Nuno Costa , Alessandra Di Pietro , Joaquim Bellmunt , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02603432
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 508)
DOI
10.1200/JCO.2023.41.6_suppl.508
Abstract #
508
Poster Bd #
K12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
First Author: Philippe Barthelemy
Poster
2021 Genitourinary Cancers Symposium
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.
First Author: Norihiko Tsuchiya
Poster
2024 ASCO Genitourinary Cancers Symposium
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
First Author: Inkeun Park
Poster
2022 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
First Author: Begoña Pérez-Valderrama